Moderna and Recipharm reached an agreement to support formulation and fill-finish a part of the Moderna COVID-19 vaccine supply outside of the US. The activity will be performed in Recipharm’s drug product manufacturing facility located in France.

Subject to regulatory approval of the vaccine in relevant countries outside of the U.S., it is anticipated that supply will commence in early 2021. Source: Genetic Engineering News 4/1/2021